Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Antiprotozoal" refers to a drug class comprised of medications used to treat infections caused by protozoa, a diverse group of unicellular eukaryotic parasites. These drugs work via various mechanisms depending on the protozoan species and the chemical class of the agent, such as disrupting DNA replication, inhibiting protein synthesis, or interfering with parasite-specific enzymes or metabolic pathways. Because protozoans are phylogenetically diverse, individual drugs may be effective against only certain pathogens. "Antiprotozoal" is not itself a molecular target, but rather a pharmacological category.
Inhibition of DNA synthesis; Disruption of protozoal cell membrane function; Inhibition of protein synthesis; Inhibition of key parasite enzymes (e.g., ornithine decarboxylase, 14-alpha-sterol demethylase, dehydrogenases); Interference with energy metabolism; Other mechanism, depending on specific agent
16 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antiprotozoal.